Gene · 6891
Papers2,915
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 2,915
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Human leukocyte antigen super-locus: nexus of genomic supergenes, SNPs, indels, transcripts, and haplotypes. | Hum Genome Var | 2022 | 36543786 | PubTator, text mining | PubMed |
| Single-cell transcriptomics highlights immunological dysregulations of monocytes in the pathobiology of COPD. | Respir Res | 2022 | 36539833 | PubTator, text mining | PubMed |
| ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma. | BMC Pulm Med | 2022 | 36539782 | PubTator, text mining | PubMed |
| m5C regulator-mediated modification patterns and tumor microenvironment infiltration characterization in colorectal cancer: One step closer to precision medicine. | Front Immunol | 2022 | 36532062 | PubTator, text mining | PubMed |
| Construction and validation of a robust prognostic model based on immune features in sepsis. | Front Immunol | 2022 | 36532037 | PubTator, text mining | PubMed |
| Immune landscape-based machine-learning-assisted subclassification, prognosis, and immunotherapy prediction for glioblastoma. | Front Immunol | 2022 | 36532035 | PubTator, text mining | PubMed |
| Galectin-9 expression clinically associated with mature dendritic cells infiltration and T cell immune response in colorectal cancer. | BMC Cancer | 2022 | 36527024 | PubTator, text mining | PubMed |
| Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity. | Front Oncol | 2022 | 36523977 | PubTator, text mining | PubMed |
| Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch. | J Immunother Cancer | 2022 | 36521927 | PubTator, text mining | PubMed |
| Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. | Front Pharmacol | 2022 | 36518661 | PubTator, text mining | PubMed |
| An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. | Front Immunol | 2022 | 36505399 | PubTator, text mining | PubMed |
| Functional Implications of Epstein-Barr Virus Lytic Genes in Carcinogenesis. | Cancers (Basel) | 2022 | 36497262 | PubTator, text mining | PubMed |
| Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer. | Cells | 2022 | 36497098 | PubTator, text mining | PubMed |
| Proteogenomic characterization of MiT family translocation renal cell carcinoma. | Nat Commun | 2022 | 36470859 | PubTator, text mining | PubMed |
Corrigendum to "Structural determinants of peptide-dependent TAP1-TAP2 transit passage targeted by viral proteins and altered by cancer-associated mutations" [Comput. Struct. Biotechnol. J. 19 (2021) 5072-5091]. | Comput Struct Biotechnol J | 2022 | 36467584 | PubTator, text mining | PubMed |
| Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism. | J Transl Med | 2022 | 36463238 | PubTator, text mining | PubMed |
| The β-carboline Harmine improves the therapeutic benefit of anti-PD1 in melanoma by increasing the MHC-I-dependent antigen presentation. | Front Immunol | 2022 | 36458012 | PubTator, text mining | PubMed |
| Pan-cancer landscape of AID-related mutations, composite mutations, and their potential role in the ICI response. | NPJ Precis Oncol | 2022 | 36456685 | PubTator, text mining | PubMed |
| Immune gene expression analysis indicates the potential of a self-amplifying Covid-19 mRNA vaccine. | NPJ Vaccines | 2022 | 36443317 | PubTator, text mining | PubMed |
| The mechanisms on evasion of anti-tumor immune responses in gastric cancer. | Front Oncol | 2022 | 36439472 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6891/papers?page=18